Shares of Amgen fell 3 percent in extended trading after the company issued weak 2019 guidance, which overshadowed its better-than-expected fourth-quarter earnings, after the market close on Tuesday.
similar news from Pfizer earlier Tuesday, which also posted strong fourth-quarter results but issued weak 2019 guidance.
Shares of Amgen have fallen about 3 percent over the past year.